None listed
Conditions
Interventions
Dietary Supplement : · Test group: 250 mg/day of pig brain enzyme hydrolysate (once a day, 1 capsule) for a total of 24 weeks
· Control: 250 mg/day (once a day, 1 capsule) as microcrystalline cellulo
Sponsors
Cheonan Korean Medicine Hospital of Daejeon University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Men and women aged 45 to 70 as of the screening date 2. a person who has graduated from elementary school or higher 3. Those with a standard score of 86 or higher in the "Korean version of the Memory Evaluation Test (K-MAS)" 4. A person who, having heard and fully understood the detailed explanation of this human body test, voluntarily decides to participate and agrees in writing to comply with the precautions 5. A person who can be followed up during the human body test period 6. A person with a sub-scale score of 10 or less for anxiety or depression on the HADS (Hospital Anxiety and Depression Scale) 7. A person who is not included in the exclusion criteria
Exclusion criteria
Exclusion criteria: 1. A person who is undergoing treatment or has a medical history of physical diseases such as neurodegenerative diseases (dementia, Parkinson's disease, etc.), head trauma, stroke, etc. that may affect memory 2. A person who has had the experience of taking medicines or health functional foods that may affect memory within four weeks from the screening date 3. A person who has a hypersensitivity reaction, such as allergies, to the food for testing 4. A person who is being treated for liver cancer or cirrhosis, chronic renal failure, congestive heart failure, etc 5. A person who is taking drugs (antihistamines, nonsteroidal anti-inflammatory drugs, adrenocortical hormones, antibiotics, antihypertensive drugs, etc.) that may affect the interpretation and evaluation of the results 6. A person who has a history of taking drugs due to hypothyroidism or hyperactivity within one year from the screening date (Those who are deemed by the tester to be able to participate in this test can participate) 7. A person who has severe migraines within one year as of the screening date, has been diagnosed with thromboembolism, cerebrovascular disease, myocardial infarction, unstable angina, or has a history of coronary angioplasty 8. A person who has severe mental illness such as depression or anxiety disorder, or is currently taking mental nervous system drugs such as antidepressants 9. Diabetic patients whose blood sugar is not controlled (more than 180 mg/dL of fasting blood or starting anew due to diabetes within 3 months) 10. a drug or alcohol addict 11. ALT (Alanine transaminase) or AST (Aspartate transaminase) in excess of 2.5 times the upper limit of the operator 12. A person whose creatine exceeds 2.5 times the normal upper limit of the research institute 13. Those who have participated in other clinical trials within one month of the commencement of this trial or are planning to participate in other clinical trials during the trial period 14. A woman who has not implemented appropriate contraception (hormone contraceptives: oral contraceptives, etc., intrauterine contraceptives: loop, etc., blocking contraception: femidome, intravenous control, etc.) among pregnant women, lactating women who are likely to become pregnant 15. Persons housed in collective facilities such as social welfare facilities 16. A person who has difficulty in daily communication due to obstacles such as vision, hearing, etc. or who has difficulty in taking notes due to physical disabilities 17. Other persons deemed unsuitable by the tester's judgment 18. A person who has a history of surgery with general anesthesia within the last three months
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Changes in the standard score of the overall memory score of the "Korean version of the K-MAS" | — |
Secondary
| Measure | Time frame |
|---|---|
| Changes in the short-term memory standard score of the Korean version of the Memory Evaluation Test (K-MAS);Changes in the standard score of language memory in the Korean version of the Memory Evaluation Test (K-MAS);Changes in the standard score of visual memory in the Korean version of the Memory Evaluation Test (K-MAS);Changes in the Attention Memory Standard Score of the Korean version of the Memory Evaluation Test (K-MAS);Change in Digit Span score;Changes in ß-amyloid protein in blood;Changes in blood BDNF(Brain-derived neurotrophic factor) | — |
Countries
Korea, Republic of
Contacts
Public ContactJae-hui Kang
Cheonan Korean Medicine Hospital of Daejeon University
Outcome results
None listed